A high-level overview of CSPC Pharmaceutical Group Limited (CHJTF) stock. View (CHJTF) real-time stock price, chart, news, analysis, analyst reviews and more.

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

The keen interest from Big Pharma has also excited the stock market. After the Otsuka deal was announced, HBM's share price ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

AstraZeneca chief executive Sir Pascal Soriot is reportedly considering the move due to growing frustration with the UK's ...

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC ...

Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation ...

Deep DockingTM & EnkiTM : Rakovina holds exclusive licenses to two breakthrough AI discovery platforms capable of analyzing billions of chemical structures at 100x the speed of traditional methods - ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

AstraZeneca has entered a strategic research collaboration with China's CSPC Pharmaceutical Group, aiming to accelerate the discovery of novel oral therapies for chronic diseases. The partnership, ...

AstraZeneca is paying China’s CSPC Pharmaceutical $110 million upfront to discover new oral drugs for chronic diseases, including one potential project for immunological diseases. The deal ...

AstraZeneca partners with China's CSPC for AI-based drug development AstraZeneca has entered a partnership with CSPC Pharmaceuticals to develop new oral treatments for chronic disease.